Structure toxicity relationships - How useful are they in predicting toxicities of new drugs?

Advances in Experimental Medicine and Biology

Volumn 500, Issue , 2001, Pages 33-43

  Nelson, Sidney D ^a  

^a UNIVERSITY OF WASHINGTON   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BICALUTAMIDE; BROMFENAC; CLOPIDOGREL; CLOZAPINE; EBROTIDINE; ENOXACIN; FAMOTIDINE; FLUTAMIDE; NILUTAMIDE; NIMESULIDE; NITROFURANTOIN; NONSTEROID ANTIINFLAMMATORY AGENT; OLANZAPINE; PIOGLITAZONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; ROSIGLITAZONE; SUPROFEN; TEMAFLOXACIN; TENIDAP; THIAZOLIDINE DERIVATIVE; THIOPHENE; TIAPROFENIC ACID; TICLOPIDINE; TIENILIC ACID; TOLCAPONE; TROGLITAZONE; TROVAFLOXACIN; ZOMEPIRAC;

ANAPHYLAXIS; BLOOD CLOTTING DISORDER; CONFERENCE PAPER; DRUG MONITORING; DRUG STRUCTURE; DRUG TRANSFORMATION; HEMOLYTIC ANEMIA; KIDNEY FAILURE; LIVER TOXICITY; PRIORITY JOURNAL; STRUCTURE ACTIVITY RELATION;

EID: 0035701966     PISSN: 00652598     EISSN: None     Source Type: Book Series    
DOI: 10.1007/978-1-4615-0667-6_4     Document Type: Conference Paper

References (67)

1. Hepatocellular injury in a patient receiving rosiglitazone
2. A reevaluation of the clinical characteristics of clozapine-induced agranulocytosis in light of the United States Experience
3. 2-receptor antagonist
4. Fulminant liver failure associated with flutamide therapy for hirsutism
5. Tolcapone and fulminant hepatitis
6. Drug discontinuations in the United Kingdom and the United States, 1964 to 1983: Issues of safety
7. Drug safety discontinuations in the United Kingdom, the United States, and Spain from 1974 through 1993: A regulatory perspective
8. Nimesulide and neonatal renal failure
9. Diclofenac-associated hepatotoxicity: Analysis of 180 cases reported to the Food and Drug Administration as adverse reactions
10. Human anti-endoplasmic reticulum autoantibodies appearing in a drug-induced hepatitis are directed against a human liver cytochrome P-450 that hydroxylates the drug
11. Olanzapine-induced neutropenia after clozapine-induced neutropenia
12. Predictability of the covalent binding of acidic drugs in man
13. Thrombotic thrombocytopenic purpura associated with ticlopidine: A review of 60 cases
14. Thrombotic thrombocytopenic purpura associated with clopidrogel
15. Inhibition by nilutamide of the mitochondrial respiratory chain and ATP formation. Possible contribution to the adverse effects of this antiandrogen
16. Development of dapsone toxicity in patients with inflammatory dermatoses: Activity of acetylation and hydroxylation as risk factors
17. Temafloxacin syndrome
18. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: Use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds
19. Acute pulmonary injury in rats by nitrofurantoin and modification by vitamin E, dietary fat and oxygen
20. Anaphylactoid reactions to tolmetin after interrupted dosage
21. Possible mechanism of liver necrosis caused by aromatic organic compounds
22. Nephrotic syndrome with Tolmetin
23. Acute eosinophilic hepatitis from trovofloxacin
24. Renal syndromes associated with non-steroidal anti-inflammatory drugs
25. Sulfamethoxazole is metabolized to the hydroxylamine in humans
26. Excretion and metabolism of trovofloxacin in humans
27. Possible role of free radical formation in clozapine (clozaril)-induced agranulocytosis
28. Hepatic failure in a patient taking rosiglitazone
29. Disposition and metabolism of tenidap in the rat
30. The safety of newly approved medicines: Do recent market removals mean there is a problem?
31. Comparison of the oxidation of clozapine and olanzapine to active metabolites and the toxicity of these metabolites to human leukocytes
32. Severe interstitial cystitis caused by tiaprofenic acid
33. Simultaneous liver and lung toxicity related to the nonsteroidal antiandrogen nilutamide (Anandron): A case report
34. Metabolic activation and immunochemical localization of liver protein adducts of the nonsteroidal antiinflammatory drug diclofenac
35. Cytotoxicity of sulfonamide reactive metabolites: Apoptosis and selective toxicity of CD8+ cells by the hydroxylamine of sulfamethoxazole
36. Adverse reactions to nitrofurantoin
37. Antimyeloperoxidase antibodies and adverse reactions to clozapine
38. Disposition and biotransformation of the antipsychotic agent olanzapine in humans
39. Diclofenac covalent protein binding is dependent on acyl glucuronide fomation and is inversely related to P450-mediated acute cell injury in cultured rat hepatocytes
40. Metabolism of ticlopidine by activated neutrophils: Implications for ticlopidine-induced agranulocytosis
41. The metabolic formation of reactive intermediates from clozapine, a drug associated with agranulocytosis in man
42. Olanzapine-induced agranulocytosis
43. Metabolic activation and drug toxicity
44. Agranulocytosis caused by ticlopidine and its mechanism
45. Neonatal end-stage renal failure associated with maternal ingestion of cyclo-oxygenase-type-2 selective inhibitor nimesulide as tocolytic
46. Nilutamide pneumonitis: A report of eight patients
47. Idiosyncratic drug reactions: Metabolic bioactivation as a pathogenic mechanism
48. Combined nitrofurantoin toxicity to liver and lung
49. Detection of adducts of bromobenzene 3,4-oxide with rat liver microsomal protein sulfhydryl groups using specific antibodies
50. Autoimmune reactions induced by procainamide and hydralazine
51. Apparent anaphylactic reaction to zomepirac (Zomax)
52. Which is the optimal antiandrogen for use in combined androgen blockade of advanced prostate cancer? The transition from a first- to second-generation antiandrogen
53. Multisystem failure and hepatic microvesicular fatty metamorphosis associated with tolmetin ingestion
54. Metabolic activation of diclofenac by human cytochrome P450 3A4: Role of 5-hydroxydiclofenac
55. Molecular mechanisms of nitrofurantoin-induced hepatocyte toxicity in aerobic versus hypoxic conditions
56. Acyl glucuronides revisited: Is the glucuronidation process a toxification as well as detoxification mechanism?
57. Roles of human hepatic cytochrome P450s 2C9 and 3A4 in the metabolic activation of diclofenac
58. Recurrence and specificity of nephrotic syndrome due to tolmetin
59. Ticlopidine-induced aplastic anemia: Case report and review of the literature
60. Drug metabolism by leukocytes and its role in drug-induced lupus and other idiosyncratic drug reactions
61. Renal failure and tubular dysfunction due to zomepirac therapy
62. Flutamide hepatotoxicity
63. Oxidation of troglitazone to a quinone-type metabolite catalyzed by cytochrome P-450 2C8 and P-450 3A4 in human liver microsomes
64. Ticrynafen-associated hepatic injury: Analysis of 340 cases